⌘K
t
MGC Pharmaceuticals Ltd (MGC Pharma) published its half year financial report. This report covers the period ended 31 December 2023 and was released on 29 February 2024.
| Date | 29 Feb 2024 |
| Time | 09:36:13 |
| Category | Miscellaneous |
| ID | 9608E |
MGC Pharmaceuticals Ltd
Half Year Financial Report
29 February 2024
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ("MGC Pharma" or the "Company"), a European based pharmaceutical company specialising in the production and development of plant derived medicines, has today published its half year financial report for the period ended 31 December 2023.
The report can be found following the link below:
https://www.investi.com.au/api/announcements/mxc/178a791e-c71.pdf
-Ends-
Authorised for release by the board of directors, for further information please contact:
|
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 |
MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6382 3390 |
|
UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 |
UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.
The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.
MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.
With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.
Follow us through our social media channels:
LinkedIn: MGC Pharmaceuticals Ltd.
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Instagram: @mgc_pharma